Medicenna Therapeutics Corp (MDNAF)

OTC Markets


	Symbol		Exchange		Currency
	MDNA		Toronto		CAD	Real-time
	MDNAF		OTC Markets		USD	Delayed

Currency in USD

0.9950

0.0000(0.00%)

Delayed Data17/01

Fair Value

Day's Range

0.9200

1.0150

52 wk Range

0.3030

2.1740

MDNAF Income Statement

Explore the detailed Medicenna Therapeutics Corp income statement, offering a comprehensive view of the company’s financial performance. Review essential metrics such as revenue, gross profit, operating income, and net income over selected periods. This page provides a clear breakdown of profitability and operational efficiency, helping you evaluate Medicenna Therapeutics Corp's growth trends and overall financial health.

Advanced Income Statement

Period Ending:

2015

31/03

2016

31/03

2017

31/03

2018

31/03

2019

31/03

2020

31/03

2021

31/03

2022

31/03

2023

31/03

2024

31/03

Total Revenues

-

-

-

-

-

Total Revenues Growth

-

-

-

-

-

Cost Of Revenues

-

-

-

-

-

Gross Profit

-

-

-

-

-

Gross Profit Growth

-

-

-

-

-

Gross Profit Margin %

-

-

-

-

-

Other Operating Expenses, Total

8.25

17.4

22.47

16.3

18.67

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+74.41%	+110.98%	+29.19%	-27.46%	+14.54%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	5.87	10.87	14.72	9.3	10.8
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	2.38	6.53	7.76	7	7.87
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

-8.25

-17.4

-22.47

-16.3

-18.67

Operating Income Growth

-74.41%

-110.98%

-29.19%

+27.46%

-14.54%

EBIT Margin %

-

-

-

-

-

Net Interest Expenses

0.01

0.31

0.07

0.91

1.2

Net Interest Expenses Growth

+6,762.75%

+4,385.71%

-78.03%

+1,224.64%

+31.07%

Interest Expense, Total

-

-

-

-

-

Interest And Investment Income

0.01

0.31

0.07

0.91

1.2

Other Non Operating Expenses, Total

-0.04

-0.21

-0.17

5.34

-7.99

EBT, Excl. Unusual Items

-8.28

-17.29

-22.58

-10.05

-25.47

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-

-

-

-

-

EBT, Incl. Unusual Items

-8.28

-17.29

-22.58

-10.05

-25.47

EBT, Incl. Unusual Items Growth

-75.81%

-108.88%

-30.59%

+55.49%

-153.44%

EBT, Incl. Unusual Items Margin

-

-

-

-

-

Income Tax Expense

-

-

-

-

-

Net Income to Company

-8.28

-17.29

-22.58

-10.05

-25.47

Minority Interest

-

-

-

-

-

Net Income

-8.28

-17.29

-22.58

-10.05

-25.47

Net Income Growth

-75.81%

-108.88%

-30.59%

+55.49%

-153.44%

Net Income Margin %

-

-

-

-

-

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

-8.28

-17.29

-22.58

-10.05

-25.47

Basic EPS - Continuing Operations

-0.26

-0.35

-0.42

-0.16

-0.37

Basic EPS - Continuing Operations Growth

-41.5%

-34.17%

-19.46%

+62.68%

-135.61%

Diluted EPS - Continuing Operations

-0.26

-0.35

-0.42

-0.16

-0.37

Diluted EPS - Continuing Operations Growth

-41.5%

-34.17%

-19.46%

+62.68%

-135.61%

Basic Weighted Average Shares Outstanding

31.9

49.66

54.29

64.74

69.64

Diluted Weighted Average Shares Outstanding

31.9

49.66

54.29

64.74

69.64

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

-8.24

-17.36

-22.44

-16.3

-18.67

EBITDA Growth

-74.5%

-110.7%

-29.27%

+27.35%

-14.55%

EBITDA Margin %